An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects

Trial Profile

An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs PEG loxenatide (Primary) ; Warfarin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Jiangsu Hansoh Pharmaceutical
  • Most Recent Events

    • 09 Mar 2018 According to ChiCTR1800015049 source this study has case series and observational design keywords. I have not updated this information since this is a phase I open label study in healthy volunteers.
    • 23 Jan 2017 Status changed from not yet recruiting to completed.
    • 25 Jan 2016 Planned initiation date changed from 1 Jun 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top